It is remarkable that so few cancer drugs enter the European market with any clear data on outcomes that matter to patients and their doctors
Medicine
Almost two thirds (57%) of cancer drugs authorised by the European Medicines Agency (EMA) between 2009 and 2013 came onto the market without any clear evidence they improved the quality or quantity of patients’ lives, according to research from the London School of Economics and Political Science (LSE) and King’s College London, published in the BMJ today (Thursday 5 October).
lse.ac.uk/News/Latest-news-...
Clearly you would think it’s EU issue and not UK one till you read how Cancer Drugs are licenced in uk.
You would have to read How cancer drugs are licensed in the UK
Drugs go through a process to make sure they’re safe, effective and that the benefits outweigh possible side effects.
In the UK, drugs are licensed through the:
European Medicines Agency (EMA) for a Europe wide licence, under laws set by the European Commission
Medicines and Healthcare Products Regulatory Agency (MHRA) for a UK licence.
The Medicines and Healthcare products Regulatory Agency (MHRA) looks at a new drug when pharmaceutical companies want to license medicines outside of the EMA’s centralised authorisation procedure.
